Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC.
TPS and SCC serum levels were evaluated in 113 patients with primary tumors, 19 with relapse and 59 with no evidence of disease after radical treatment. Abnormal serum levels were found in 37% and 33% of patients with primary untreated tumors and in 53% and 59% of patients with relapse, respectively, using 100 U/L and 2.5 ng/ml as the upper limit of normality for TPS and SCC, respectively. Either tumor marker was abnormal in 57.5% of primary tumors and in 74% of patients with relapse. TPS and SCC serum levels were related to nodal involvement, with significantly higher levels in patients with nodal invasion (p < 0.02 and p 0.001, respectively). No relationship was found between tumor size, age or histological grade and SCC or TPS values. Pretreatment TPS and SCC serum levels had prognostic interest in patients with locoregional tumors, with a significantly shorter disease-free interval (DFI) in patients with abnormal values (p < 0.01 and p < 0.02, respectively). When tumor marker levels and nodes were simultaneously evaluated, a trend toward shorter DFI in patients with abnormal serum concentrations was found, with no statistical significance. By contrast, TPS and SCC were useful in prognosis in node-negative patients (p < 0.02 and p < 0.001, respectively). Likewise, using both TAAs simultaneously, it is possible to increase prognostic information. Patients with TPS and/or SCC abnormal levels had a significantly lower DFI than those patients with normal values, in both node positive and negative patients (P < 0.01). In summary, TPS and SCC are useful TAAs in patients with head and neck malignancies. Likewise, with the simultaneous use of SCC and TPS, the TAA utility in this malignancy increases in the prognosis as well as disease follow-up.
Molina
R
R
Laboratory of Clinical Biochemistry (Unit fro Cancer Research), Hospital Clinic, Medical School, Barcelona, Spain.
Torres
M D
MD
Moragas
M
M
Filella
X
X
Jo
J
J
Giménez
N
N
Traserra
J
J
Ballesta
A M
AM
D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D002277:Carcinoma / Q000097:blood / Q000473:pathology / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000473:pathology / Q000601:surgery; D018572:Disease-Free Survival; D006258:Head and Neck Neoplasms / Q000097:blood* / Q000473:pathology / Q000601:surgery; D006801:Humans; D008207:Lymphatic Metastasis; D009364:Neoplasm Recurrence, Local; D010455:Peptides / Q000097:blood*; D011379:Prognosis; D012680:Sensitivity and Specificity; D015843:Serpins
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D010455:Peptides; D015843:Serpins; C051072:squamous cell carcinoma-related antigen; C089984:tissue polypeptide specific antigen